Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 04, 2018

PCSK9 Monoclonal Antibodies Do Not Significantly Affect New-Onset Diabetes or Glucose Metabolism

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Monoclonal Antibodies on New-Onset Diabetes Mellitus and Glucose Metabolism: A Systematic Review and Meta-Analysis
Diabetes Obes Metab 2018 Mar 07;[EPub Ahead of Print], YX Cao, HH Liu, QT Dong, S Li, JJ Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading